Inari Medical, Inc. (NARI) Reports Preliminary Q4 Revenue

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue.

Preliminary Fourth Quarter Revenue and Business Highlights:

• Preliminary unaudited revenue is expected to be in the range of $47.9 million to $48.9 million in the fourth quarter of 2020, a 141% to 146% increase over the prior year period and 24% to 26% increase over the third quarter of 2020.
• The company completed approximately 4,600 procedures in the fourth quarter, a 156% increase over the prior year period and a 24% increase over the third quarter of 2020.

“We are pleased with our procedural growth in the fourth quarter and the opportunity to save and transform the lives of VTE patients, especially in the face of the challenges presented by the pandemic,” said Bill Hoffman, Chief Executive Officer of Inari Medical. “Our team is executing our strategic plan and we look forward to sharing our progress on our quarterly earnings call.”

The preliminary unaudited revenue results described in this press release are estimates only and subject to revision until we report our full financial results for 2020 in our Annual Report on Form 10-K.

You May Also Be Interested In

• JPMorgan is worried about further S&P 500 sell-off potential
• Globe Life Inc. (GL) Misses Q1 EPS by 1c, Offers Guidance
• Novartis (NVS) Tops Q1 EPS by 13c, raises guidance